Open AccessTherapeutic Monitoring of Voriconazole in Children Less Than Three Years of Age
Author(s) -
Elizabeth H. Doby,
Daniel K. Benjamin,
Anne J. Blaschke,
Robert M. Ward,
Andrew T. Pavia,
Paul Martin,
Timothy A. Driscoll,
Michael CohenWolkowiez,
Cassandra Moran
Publication year - 2012
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0b013e31824acc33
Subject(s) - voriconazole , medicine , therapeutic drug monitoring , aspergillosis , pharmacokinetics , pediatrics , intensive care medicine , antifungal , immunology , dermatology
Voriconazole is the treatment of choice for invasive aspergillosis and its use is increasing in pediatrics. Minimal pharmacokinetic data exist in young children. We report voriconazole concentrations for 10 children <3 years of age and pharmacokinetic parameters for 1 infant who had therapeutic drug monitoring performed. Trough concentrations were unpredictable based on dose, highlighting the need to follow values during therapy.